Abstract
Vitiligo is a common disorder of skin pigmentation resulting from autoimmune destruction of melanocytes. A variety of topical and systemic treatment options have been tried with varying success. Here we describe the case of a man with refractory vitiligo successfully treated with topical crisaborole ointment. Crisaborole ointment is a topical phosphodiesterase (PDE)-4 inhibitor recently FDA-approved for the treatment of atopic dermatitis. Previous literature has discussed the possible role of systemic PDE-4 inhibitors in vitiligo; herein, we discuss the ability of topical crisaborole to accelerate repigmentation in treatment-resistant vitiligo.
Original language | English (US) |
---|---|
Pages (from-to) | 111-113 |
Number of pages | 3 |
Journal | SKIN: Journal of Cutaneous Medicine |
Volume | 3 |
Issue number | 2 |
DOIs | |
State | Published - Mar 11 2019 |
Keywords
- PDE-4 inhibitor
- Vitiligo
- crisaborole
ASJC Scopus subject areas
- Dermatology